GlassScriptPhysician profile
Duncan R Chapman
NPI 1437474152
$1,537.47
in general payments reported to CMS, 2019-2025
17 companies · $23.53 in 2025
The $23.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.64 · 2023: $644 · 2024: $812 · 2025: $23.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $369.14 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $199.44 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.74 | 2023-2024 | Jardiance, Ofev, Synjardy |
| Pfizer INC. | $164.08 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.26 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $90.87 | 2023 | Gvoke Hypopen, Keveyis |
| Lilly USA, LLC | $69.11 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $66.07 | 2023-2024 | Vraylar, Qulipta |
| Smith+Nephew, INC. | $57.64 | 2020 | |
| Amgen INC. | $52.95 | 2024 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $43.76 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $27.99 | 2024 | Yupelri |
| Astellas Pharma US INC | $20.42 | 2023 | Veozah |
| Horizon Therapeutics Plc | $20.21 | 2023 | Krystexxa |
| Phadia US INC. | $17.62 | 2023 | Immunocap |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $17.42 | 2024 | Belbuca |
| Dynavax Technologies Corporation | $16.75 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duncan Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.